Login to Your Account



Financings Roundup

Tioga Nabs $18M from VCs for Phase III Irritable Bowel Studies

By Trista Morrison


Thursday, February 18, 2010
Tioga Pharmaceuticals Inc. raised $18 million in its second round of venture financing, money that will allow the San Diego biotech to complete a Phase III trial with asimadoline for diarrhea predominant irritable bowel syndrome (D-IBS). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription